| dbo:abstract |
ELB-139 (LS-191,811) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. ELB-139 is a subtype-selective partial agonist at GABAA receptors, with highest affinity for the α3 subtype, but highest efficacy at α1 and α2. It has primarily anxiolytic and anticonvulsant effects, but produces little sedative effects or ataxia, and has also been demonstrated in rats to increase serotonin levels in the striatum and prefrontal cortex, without affecting dopamine levels. It has been proposed as a possible candidate for a novel non-sedating anxiolytic or anticonvulsant drug for use in humans The sponsor elbion AG registered a clinical trial in ClinicalTrials.govfor the treatment of anxiety associated with panic disorder but the results have not been reported. It was developed by Arzneimittelwerk Dresden in the 1990s. (en) |
| dbo:casNumber |
188116-08-7 |
| dbo:fdaUniiCode |
BKP2A5554F |
| dbo:pubchem |
11277418 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/ELB-139.png?width=300 |
| dbo:wikiPageExternalLink |
http://clinicaltrials.gov/ct2/show/study/NCT00322803 |
| dbo:wikiPageID |
18766868 (xsd:integer) |
| dbo:wikiPageLength |
5673 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
983314786 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Partial_agonist dbr:Benzodiazepine dbr:Anticonvulsant dbc:Chloroarenes dbc:GABAA_receptor_positive_allosteric_modulators dbc:Imidazolines dbc:Lactams dbc:Piperidines dbc:Ureas dbr:Anxiolytic dbr:Dissociation_constant dbc:Anxiolytics dbr:Nonbenzodiazepine dbr:Prefrontal_cortex dbr:Ataxia dbr:Efficacy dbr:Dopamine dbr:Sedative dbr:Serotonin dbr:Striatum dbr:GABA_A_receptor |
| dbp:c |
14 (xsd:integer) |
| dbp:casNumber |
188116 (xsd:integer) |
| dbp:chemspiderid |
9452418 (xsd:integer) |
| dbp:cl |
1 (xsd:integer) |
| dbp:h |
16 (xsd:integer) |
| dbp:iupacName |
1 (xsd:integer) |
| dbp:n |
3 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
11277418 (xsd:integer) |
| dbp:smiles |
Clc3cccN1CCN2CCCCC2 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
YGXIELIREXEJQN-UHFFFAOYSA-N (en) |
| dbp:unii |
BKP2A5554F (en) |
| dbp:verifiedrevid |
451925233 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:GABAAR_PAMs dbt:Not_a_typo dbt:Cascite dbt:Drugbankcite dbt:Fdacite dbt:Anxiolytics dbt:Anxiolytic-stub |
| dcterms:subject |
dbc:Chloroarenes dbc:GABAA_receptor_positive_allosteric_modulators dbc:Imidazolines dbc:Lactams dbc:Piperidines dbc:Ureas dbc:Anxiolytics |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatUreas yago:Abstraction100002137 yago:Chemical114806838 yago:Compound114818238 yago:Material114580897 yago:Matter100020827 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Urea115085472 umbel-rc:DrugProduct |
| rdfs:comment |
ELB-139 (LS-191,811) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. (en) |
| rdfs:label |
ELB-139 (en) |
| owl:sameAs |
freebase:ELB-139 yago-res:ELB-139 wikidata:ELB-139 dbpedia-sh:ELB-139 dbpedia-sr:ELB-139 https://global.dbpedia.org/id/4igW1 |
| prov:wasDerivedFrom |
wikipedia-en:ELB-139?oldid=983314786&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/ELB-139.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:ELB-139 |
| is dbo:wikiPageWikiLink of |
dbr:C14H16ClN3O dbr:Nonbenzodiazepine |
| is foaf:primaryTopic of |
wikipedia-en:ELB-139 |
